PDF Inhibitors: An Emerging Class of Antibacterial Drugs

Author(s): K. W. Johnson, D. Lofland, H. E. Moser

Journal Name: Current Drug Targets - Infectious Disorders
Continued as Infectious Disorders - Drug Targets

Volume 5 , Issue 1 , 2005


The metalloenzyme peptide deformylase (PDF) represents one of the most promising bacterial targets in the search for novel mode of action antibiotics that lack cross-resistance to existing drugs. Initial research and clinical development has focused on anti-pneumococcal applications. During optimization, peptide analogs were developed containing either a hydroxamate or formyl-hydroxylamine as metal interacting group, yielding inhibitors with in vitro activity against a broad spectrum of organisms. Preclinical studies revealed potent antibacterial activity in vivo that is paired with good pharmacokinetic properties and excellent tolerability in different species. BB-83698, a potent PDF inhibitor with i.v. and oral efficacy in preclinical animal models, represents the first class-representative compound evaluated in man. The inhibitor was administered by i.v. infusion and was shown to exhibit generally dose-proportional pharmacokinetics. It was well tolerated up to doses providing predicted therapeutic exposures. These human results, combined with the preclinical information, clearly support the potential of PDF inhibitors for development as a novel class of antibacterial therapeutics.

Keywords: peptide deformylase, review, antibiotics, enzyme inhibitor, peptide analogs, pharmacology, pharmacokinetics

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [39 - 52]
Pages: 14
DOI: 10.2174/1568005053174618

Article Metrics

PDF: 15